High Vitamin D Consumption Is Inversely Associated with Cardiovascular Disease Risk in an Urban Mexican Population

Paloma Muñoz-Aguirre1☯, Edgar Denova-Gutiérrez2☯∗, Mario Flores3‡, Eduardo Salazar-Martínez4‡, Jorge Salmerón1,4○

1 Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Cuernavaca, Morelos, México, 2 Unidad de Investigación en Epidemiología Clínica, Hospital Infantil de México “Federico Gómez”, Ciudad de México, México, 3 Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México, 4 Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
○ edenovag@gmail.com

Abstract

Background

Vitamin D deficiency is a major global public health problem. Recent epidemiological studies have assessed the relationship between vitamin D and multiple outcomes, including cardiovascular disease. However, this evidence is limited and inconclusive. Our purpose in this study was to evaluate the association between dietary vitamin D intake and cardiovascular disease risk in adult Mexican population.

Methods

We conducted a cross-sectional analysis with the baseline data from 6294 men and women aged 20–80 years participating in the Health Workers Cohort Study. Data on sociodemographic, lifestyle, and medical history factors were collected with a self-administered questionnaire. Dietary intake was evaluated by using a semi-quantitative food-frequency questionnaire. Cardiovascular disease risk was calculated using a recalibration of the Framingham heart disease prediction score. To evaluate the association between vitamin D intake and 10-year cardiovascular disease risk, odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using multiple logistic regression analysis.

Results

A total of 6294 subjects (1820 men and 4474 women) with a mean age of 42 years, were included. Of these, subjects in the highest quintile of vitamin D intake presented lower levels of triglycerides 14.6 mg/dL (P for trend = 0.001); 2.0 cm less in waist circumference (P for trend = 0.001) and 0.8 points less in the Framingham cardiovascular disease risk score (P for trend = 0.002) compared with the subjects in the lower quintile of vitamin D intake. Additionally, participants in the highest quintile of vitamin D consumption were less likely to...
develop elevated 10-year cardiovascular disease risk, compared with those in the lowest quintile (OR = 0.51; 95%CI: 0.33, 0.77; \( P \) for trend = 0.007).

**Conclusion**

Our data suggest that higher consumption of vitamin D is associated with a reduced risk of cardiovascular disease in Mexican population.

**Introduction**

Vitamin D (VD) is a prohormone whose main function is to regulate calcium and phosphorus metabolism related to preserve bone mass [1]. Due to the fact that VD has a wide distribution in the body tissues, other important functions have been discovered, such as the modulation of cell growth, immune function and reduction of inflammation [2,3].

In humans, VD is primarily obtained through sun exposure, because very few foods naturally contain vitamin D, diet and dietary supplements are other sources of VD; consequently, the assessment of dietary intake of VD is valuable for nutritional epidemiological studies [4]. Vitamin D deficiency has been identified as a public health issue [4]. Whereas, in Mexican adult population, the prevalence of deficiency in 2006 was 2.0% (serum 25-OH-D \( <30\) nmol/L - \( <12\) ng/mL) and 9.8% had serum 25-OH-D levels \( <50\) nmol/L - \( <20\) ng/mL [5,6]. This condition could be attributed to decreased sun exposure, scarce dietary sources of vitamin D and an increased prevalence of obesity [7].

Cardiovascular disease (CVD) is the leading cause of death and a major cause of disability worldwide [8], and the main cause of mortality in Mexican adults [9]. Epidemiological studies have suggested that lifestyle, including diet, significantly influences CVD occurrence [10]. Previous research [4, 11–13] has suggested a possible relationship between VD, CVD, and other chronic diseases. In this sense, a recent clinical trial conducted by Zitterman et al. have documented the effect of daily vitamin D supplements on CVD markers and they found that a daily vitamin D supplement (83 \( \mu \)g/day) is able to improve several cardiovascular disease risk markers such as triglycerides, inflammation marker tumor necrosis factor-\( \alpha \), endothelial function and cardiac function in overweight subjects with inadequate vitamin D status [14]. Nevertheless, the effect of vitamin D on CVD is still unclear [15].

There are some plausible mechanisms that explain how vitamin D might modify cardiovascular outcomes, vitamin D regulates the renin-angiotensin system [16], suppresses proliferation of vascular cell smooth muscle [17], ameliorates insulin resistance [18] improves endothelial cell-dependent vasodilation [19, 20], inhibits anticoagulant activity [21] and myocardial cell hypertrophy [22, 23], and may modulate macrophage activity [24] and cytokine generation [25, 26].

There are still some questions on this issue, we do not know if optimal vitamin D consumption and concentrations are a cause or a consequence of good health. Therefore, we examined the cross-sectional relation between dietary vitamin D intake and risk of cardiovascular disease as well as cardiometabolic risk factors in subjects participating in the Health Workers Cohort Study (HWCS), in Mexico. We hypothesized that high intake of vitamin D would be negatively associated with cardiovascular disease risk, independently of demographic and lifestyle factors.
Materials and Methods

Study population

We conducted a cross-sectional analysis of data from adults participating in the baseline assessment of the Health Workers Cohort Study (HWCS). The participants in this cohort study are middle- to low-income status, residing in urban central Mexico. The study design, methodology, and participants’ characteristics have been detailed elsewhere [27–30]. Concisely, the HWCS focuses on lifestyle and chronic disease. Participants completed baseline questionnaires providing information about demographic, behavioral, and lifestyle factors; medical history including medication use; use of multivitamins and other supplements; and anthropometric measurements and clinical evaluations were performed.

For the present analysis we included 6294 subjects aged 20–80 who provided fasting blood samples (≥ 12 hours since last meal), and were not previously diagnosed with type 2 diabetes (assessed by self-report or with levels of glucose ≥ 126 mg/dL) (n = 491) or taking lipid lowering medication (n = 567). We also excluded participants who left 10 percent or more food items blank on the questionnaire (n = 635), and who did not consume between 600 kcal and 7000 kcal daily (n = 320).

This study was planned and conducted according to the guidelines laid down in the Declaration of Helsinki. All participating institutions’ research ethics committees: Comité de Ética en Investigación, Instituto Mexicano del Seguro Social (No. 12CEI 09 006 14); Comité de ética en Investigación, Instituto Nacional de Salud Pública (No. 13CEI 17 007 36); Comité de Ética, Centro de Investigación en Ciencias Médicas (No. 1233008X0236), revised and approved the study protocol and informed consent forms. Written informed consent was obtained from each participant.

Dietary and vitamin D intake assessment

Dietary intake data and VD consumption were collected using a 116-item semi-quantitative food frequency questionnaire (FFQ), previously validated in an adult Mexican population [31].

Vitamin D and other nutrient consumption were computed by multiplying the frequency of consumption of each unit of food from the FFQ by the VD and nutrient content of the specified portion size. Composition values for dietary VD and other nutrients were estimated by means of a comprehensive Mexican database of food composition [32]. Information about use of specific brand and type of multivitamins was collected by asking current users about weekly number of multivitamins taken. Total VD represented the sum of VD intake from dietary and supplemental sources. Each nutrient was adjusted for total energy using the residual method [33]. Finally, in order to compute energy consumption, the daily frequency of consumption of each food was multiplied by the food’s energy content.

Anthropometric assessment

As we reported previously [27–30], participants’ weight and height were measured by trained nurses using standardized procedures (reproducibility analysis showed concordance coefficients from 0.83 to 0.90). Weight (kg) and height squared (m²) were used to calculate body mass index (BMI kg/m²). Waist circumference was measured at the high point of the iliac crest at the end of normal expiration, to the nearest 0.1 cm, with a steel measuring tape, which was placed below any clothing, directly touching the participants’ skin. In the present study, being overweight or obese was defined as BMI ≥ 25 kg/m² [34]. Abdominal obesity was defined as a waist circumference of >102 cm in men and >88 cm in women [35].
Biomarkers assessment

A fasting venous blood sample (fasting time was 12 hours) was collected from each participant. Plasma triglycerides were measured with a colorimetric method following enzymatic hydrolysis performed with the lipase technique. High-density lipoprotein cholesterol (HDL-c) was measured by clearance method; in this method non HDL-c lipoprotein is removed in the first step of the reaction (clearance step). Low-density lipoprotein cholesterol (LDL-c) was measured by clearance method; finally, total cholesterol was measured by colorimetric method following enzymatic assay. All biomedical assays were performed using a Selectra XL instrument (Randox).

High lipid profile assessment

High lipid profile was defined according to the criteria put forth in the report of the National Cholesterol Education Program ATP-III, that defines a high lipid profile as: high serum triglycerides ≥150 mg/dL, high serum total cholesterol ≥200 mg/dL, high LDL-c ≥100 mg/dL, and low HDL-c ≤40 mg/dL in men and ≤50 mg/dL in women [35].

Cardiovascular disease risk assessment

Cardiovascular disease (CVD) risk was calculated using a recalibration of the Framingham coronary heart disease prediction scores [36, 37]. We first estimated the predicted risk of total CVD, applying the β-coefficients of Cox proportional hazards model obtained from the Framingham population by Wilson et al. [36], which included age, current smoking, type 2 diabetes, blood pressure regardless of hypertension treatment (predefined BP categories), serum LDL-c (predefined categories), and HDL-c (predefined categories). We used this equation to calculate each participant’s 10-year predicted probability of CVD.

The main outcome of the current analysis was the development of more than 10 percent risk of CVD in ten years. We defined participants as at low CVD risk when they had less than 10 percent risk in ten years. Subjects who had more than 10 percent risk in ten years were defining has having a CVD risk (moderate/elevated) by the American Heart Association standards [38].

Non-dietary variables assessment

Demographic characteristics (e.g., age, sex, and education), medical history, and lifestyle, including alcohol and tobacco consumption, were collected by means of self-administered questionnaire. Physical activity was assessed using International Physical Activity Questionnaire (IPAQ). Participants were asked about their daily recreational activity, leisure activity, daily activity and any physical labor associated with employment. Participants reported the time they spent each week on activities such as running and walking during a typical week in the previous year. Each activity was given a value in metabolic equivalent tasks (METs) and total METs per week was computed [28–30].

Statistical analysis

Descriptive analyses of the main variables of interest (including age, BMI, waist circumference, physical activity, and total energy intake, etc.) across quintiles of total vitamin D intake were performed. Analysis of variance (ANOVA) was used to evaluate mean differences across quintiles of total dietary VD consumption for continuous variables. The chi-square test was used to determine differences in the distribution of categorical variables across VD quintiles.
The influence of the total dietary VD intake on lipid profile, BMI, abdominal obesity, and scores of CVD risk was evaluated using multivariate linear regression models in which these variables were analyzed as a continuous.

Finally, to estimate the magnitude of the association between specific categories of total dietary VD intake and abnormal lipids profile, obesity, abdominal obesity, as well as elevated CVD risk, we computed adjusted odds ratios (OR) and 95% confidence intervals (95% CI) using multiple logistic regression models.

To assess possible effect modification, we explored analyses stratified by body mass index (two categories: <25 kg/m² vs ≥ 25 kg/m²). We tested the significance of the interaction with a likelihood ratio test by comparing a model with the main effects of each intake and the stratifying variable and the interaction terms with a reduced model with only the main effects.

All P values presented are two sided; P < 0.05 was considered statistically significant. The statistical analyses were performed using the STATA statistical software package, version 13.0 (Stata Corp. LP: College Station, TX).

Results

Participants’ baseline characteristics (age, sex, body composition, clinical parameters, and dietary information) are shown in Table 1. A total of 6294 subjects (1820 men and 4474 women) with a mean age of 42 years, were included in the final analysis. Of these, the corresponding median intakes in the lowest and highest quintiles were 70.4 and 516.2 international units (IU) of vitamin D₃ (cholecalciferol) respectively. A higher VD intake was observed in subjects with lower BMI, fewer prevalence of overweight and obesity and abdominal obesity, increased physical activity levels, decreased use of tobacco, and increased use of multivitamins (P for trend <0.001) were observed across increasing VD quintiles. In addition, subjects in the highest quintile of VD intake had a lower prevalence of diabetes and lipid abnormalities compared with subjects in the lowest quintile of VD consumption. Finally, data shows that subjects in the highest quintile of VD intake have a lower likelihood of >10% risk of 10-year cardiovascular disease than those in the lowest quintile.

The effect of VD on cardiovascular risk markers is shown on Table 2. After adjusting for age, sex, multivitamin use, BMI, physical activity, alcohol, saturated fats, polyunsaturated fats, fiber, energy, glycemic load, smoking status, postmenopausal hormone use, place of residence and season we observed that subjects in the highest quintile of VD intake presented a decrease of 14.6 mg/dL in triglycerides (P for trend = 0.01); 0.9 kg/m² in BMI (P for trend <0.001); 2.0 cm in waist circumference (P for trend = 0.001) and 0.8 points in the Framingham cardiovascular risk score (P for trend = 0.002) compared with the subjects in the lower VD category.

Table 3 shows the ORs and 95% CIs of a multiple logistic regression analysis evaluating the association between VD intake, CVD, obesity, abdominal obesity and cardiometabolic risk factors. After adjustment for lifestyle and dietary covariates, total VD intake was inversely associated with some cardiometabolic risk factors such as low HDL-c, hypertriglyceridemia, obesity, and abdominal obesity. For example: subjects in the higher category of VD intake had lower odds of presenting low HDL-c (OR = 0.65; 95%CI: 0.52, 0.82), hypertriglyceridemia (OR = 0.72; 95%CI: 0.59, 0.88), obesity (OR = 0.74; 95%CI: 0.61, 0.90), and abdominal obesity (OR = 0.74; 95%CI: 0.60, 0.91). Additionally, participants in the highest quintile of VD consumption were less likely to develop elevated 10-year CVD risk, compared with those in the lowest quintile (OR = 0.51; 95%CI: 0.33, 0.77; P for trend = 0.007).

We examined the joint effect of VD intake and body mass index by cross classifying the study population by both variables. The odds ratio from these stratified analyses was 1.61 (95% CI: 1.08–2.57; P for interaction <0.001) when subjects with low VD consumption and
overweight/obesity were compared with subjects with a low consumption of VD and body mass index $< 25 \text{ kg/m}^2$ (Fig 1).

**Discussion**

To the best of our knowledge, this is the first study assessing the association between VD intake and CVD risk in Mexican adult population. We found that our study population on average consumed less VD than the recommended daily allowance [39]. As we reported in a previous study, approximately 96% of men and women had inadequate intake of VD [40].
These findings are similar to those observed in another adult population [41, 42]. For example, Bailey et al. [41], found that approximately 95% of women and 96% of men in the US had inadequate consumption of VD. The inadequate consumption of VD in the diet is explained easily since VD is found in only few foods and in low amounts.

Table 2. Multivariate regression model for evaluating the association between vitamin D intake and cardiovascular risk markers in a Mexican adult population.

| Variables                  | Quintiles of vitamin D intake | Q1      | Q2             | Q3   | Q4           | Q5      | P for trend* |
|----------------------------|--------------------------------|---------|----------------|------|-------------|---------|-------------|
|                            |                                | β       | (95% CI)       | β   | (95% CI)    | β       | (95% CI)    |            |
| Total cholesterol, mg/dL\(^a\) | 0.0                            | 2.2     | (-0.7, 5.2)    | 1.8 | (-1.2, 4.9) | 2.9     | (-0.5, 6.5) | 2.6         | (-0.4, 5.9) | 0.101   |
| HDL Cholesterol, mg/dL\(^a\)  | 1.1                            | (-0.2, 2.0) | 1.3 | (0.3, 2.2) | 1.7 | (0.6, 2.6) | 2.8     | (1.6, 4.1)  | <0.001 |
| LDL Cholesterol, mg/dL\(^a\)  | 1.9                            | (-1.1, 5.0) | 1.5 | (-1.5, 4.5) | 2.1 | (-0.9, 5.7) | 2.7     | (-0.6, 6.1) | 0.097   |
| Triglycerides, mg/dL\(^a\)   | -8.0                           | (-15.7, -2.2) | -9.9 | (-17.8, -1.8) | -11.1 | (-19.1, -4.6) | -14.6   | (-24.3, -4.9) | 0.01    |
| Body mass index, kg/m\(^2\)b | -0.07                          | (-0.4, 0.2) | -0.2 | (-0.6, 0.1) | -0.5 | (-0.8, -0.1) | -0.9    | (-1.2, -0.3) | <0.001 |
| Waist circumference, cm\(^b\) | -0.7                           | (-1.6, 0.2) | -0.8 | (-1.8, 0.8) | -1.4 | (-2.4, -0.4) | -2.0    | 0 (-3.1, -0.9) | 0.001  |
| Cardiovascular disease risk\(^c\) | -0.3                           | (-0.8, 0.1) | -0.3 | (-0.7, 0.3) | -0.5 | (-0.8, 0.2) | -0.8    | (-1.4, -0.3) | 0.002   |

*Test for linear trend.
\(^a\) Model adjusted for age (years), sex, multivitamin use (yes or not), BMI (continuous), physical activity (quintiles), alcohol, saturated and polyunsaturated fats (quintiles), fiber (quintiles), energy (quintiles), glycemic load (quintiles), current smoking (never, past or current), postmenopausal hormone use (yes or not).
\(^b\) Model adjusted for age (years), sex, multivitamin use (yes or not), physical activity (quintiles), alcohol intake (quintiles), saturated and polyunsaturated fats (quintiles), fiber, energy (quintiles), glycemic load (quintiles), place of residence, season, postmenopausal hormone use (yes or not) and history of myocardial infarction (yes or not).

Table 3. Multivariate logistic regression model for evaluating the association between vitamin D intake and cardiovascular risk markers in a Mexican adult population.

| Variables                        | Quintiles of vitamin D intake | Q1 OR (95% CI) | Q2 OR (95% CI) | Q3 OR (95% CI) | Q4 OR (95% CI) | Q5 OR (95% CI) | P for trend* |
|----------------------------------|--------------------------------|----------------|----------------|----------------|----------------|----------------|-------------|
| Hypercholesterolemia\(^a\)       | 1.0                            | 1.05 (0.89, 1.24) | 1.12 (0.93, 1.34) | 1.17 (0.96, 1.40) | 1.15 (0.92, 1.43) | 0.174          |
| Hypoalphalipoproteinemia\(^a\)   | 1.0                            | 0.80 (0.69, 0.96) | 0.83 (0.68, 1.03) | 0.76 (0.64, 0.93) | 0.65 (0.52, 0.82) | <0.001         |
| Elevated LDL-c\(^a\)             | 1.0                            | 1.07 (0.92, 1.21) | 0.99 (0.82, 1.18) | 1.09 (0.92, 1.29) | 0.93 (0.74, 1.15) | 0.682          |
| Hypertriglyceridemia\(^a\)       | 1.0                            | 0.83 (0.70, 0.98) | 0.87 (0.73, 1.03) | 0.77 (0.64, 0.92) | 0.72 (0.59, 0.88) | 0.006          |
| Overweight and obesity\(^b\)     | 1.0                            | 0.99 (0.85, 1.19) | 0.94 (0.80, 1.13) | 0.79 (0.63, 0.92) | 0.74 (0.61, 0.90) | <0.001         |
| Abdominal obesity\(^b\)          | 1.0                            | 0.91 (0.76, 1.09) | 0.93 (0.77, 1.12) | 0.82 (0.67, 0.99) | 0.74 (0.60, 0.91) | 0.007          |
| Medium/high predicted cardiovascular disease risk\(^c\) | 1.0                            | 0.93 (0.72, 1.26) | 0.87 (0.61, 1.22) | 0.69 (0.53, 1.09) | 0.51 (0.33, 0.77) | 0.007          |

*To assess the overall trend of OR across increasing quintile of dietary pattern scores we computed the Mantel-Haenszel extension chi-square test.
\(^a\) Model adjusted for age (years), sex, multivitamin use (yes or not), BMI (continuous), physical activity (quintiles), alcohol, saturated and polyunsaturated fats (quintiles), fiber (quintiles), energy (quintiles), glycemic load (quintiles), current smoking (never, past or current), postmenopausal hormone use (yes or not).
\(^b\) Model adjusted for age (years), sex, multivitamin use (yes or not), physical activity (quintiles), alcohol intake (quintiles), saturated and polyunsaturated fats (quintiles), fiber, energy (quintiles), glycemic load (quintiles), place of residence, season, postmenopausal hormone use (yes or not) and history of myocardial infarction (yes or not).

doi:10.1371/journal.pone.0166869.t002
doi:10.1371/journal.pone.0166869.t003
In literature, no studies have investigated the association between dietary VD and cardiovascular disease risk factors. Despite the fact, in a set of cross-sectional studies [43–47], the relationship between VD and cardiovascular disease risk factors have been evaluated considering serum levels of VD. In our population, the average blood plasma concentrations of triglycerides, waist circumference, and BMI decreased across the quartiles of VD intake. In addition, we found that blood plasma concentrations of HDL-c increased as dietary VD intake increased. As we noted above, most cross-sectional studies [43–49], high serum VD have been related to lower triglyceride blood plasma concentrations [40–45], and higher HDL-c levels [43–48]. Furthermore, our analyses shows that subjects in the highest quintile of VD intake would entail on average 14.6 mg/dL deficit of triglycerides and a 2.8 mg/dL excess of HDL-c, compared to the average levels of our study population. Similar to our results Ramly and coworkers, in a clinical trial [50], found that subjects who receiving VD had on average 11.2 mg/dL lower concentrations of triglycerides and 0.8 mg/dL higher concentrations of HDL-c compared with subjects who did not receive VD. Additionally, our results suggest that subjects in the highest quintile of VD intake had on average 0.9 lower units (kg/m$^2$) of BMI, and 2.0 cm in waist circumference. In accordance with this result, other studies [43–45] have reported that higher serum levels of VD are associated with lower waist circumference (on average between 0.4 to 3.2 cm), and lower BMI [46].

In our study, logistic regression analysis shows that subjects in the higher dietary VD group have 28% lower odds of hypertriglyceridemia ($P$ for trend = 0.006), 35% lower odds of low HDL-c, and 26% lower odds of being obese or abdominal obese than subjects in the lowest quintile of dietary VD intake. However, serum total cholesterol and LDL-c concentrations were not related to VD intakes. Compared to our results, Martins et al. [51] found that subjects in the lowest quartile of serum VD levels had higher odds of hypertriglyceridemia (OR = 1.47; 95%CI: 1.30, 1.65), higher odds of obesity (OR = 2.29; 95%CI: 1.99, 2.63).

Fig 1. Joint association of dietary vitamin D (quintiles) and body mass index (<25 kg/m$^2$ and ≥ 25 kg/m$^2$) with the predicted cardiovascular disease risk. Reference group for comparisons were subjects in lowest quintile of vitamin D intake with body mass index < 25 kg/m$^2$. Odds ratio were adjusted for: age (years), sex, multivitamin use (yes or not), BMI (continuous), physical activity (quintiles), alcohol (quintiles), saturated and polyunsaturated fats (quintiles), fiber, energy (quintiles), glycemic load (quintiles), place of residence, season, postmenopausal hormone use (yes or not) and history of myocardial infarction (yes or not).

doi:10.1371/journal.pone.0166869.g001
Our data also suggests an inverse relationship between VD intake and 10-year CVD risk. We observed that subjects in the highest quintile had 49% lower odds of 10-year CVD risk (OR = 0.51; 95% CI: 0.33, 0.77; P for trend = 0.007). This result is consistent with a study that found that subjects in the higher group of total VD intake was associated with a decreased risk of CVD; the relative risks (95% CIs) for a comparison of participants who met the Dietary Reference Intake of VD (≥ 600 IU/day) with participants whose VD intake was <100 IU/day was 0.84 (95% CI: 0.72, 0.97; P for trend = 0.009) for men and 1.02 (95% CI: 0.89, 1.17; P for trend = 0.12) for women [52]. In addition, other study conducted by Wang et al. [53] reported that subjects in the lowest category of serum VD had 81% higher risk of CVD (RR = 1.81; 95% CI: 1.03, 3.18), compared with subjects in the highest category.

Several mechanisms support the possible beneficial effects of VD on cardiovascular disease [53, 54]. First, this may be explained by the large number of receptors for VD, which are present in many cells of the cardiovascular system. Experimental evidence indicates that the active form of VD (1,25 (OH) D) inhibits the expression of the gene for renin, regulating in this way the system renin-angiotensin which results in the modulation of the growth and proliferation of vascular cells and cardiomyocytes, as well as processes of inflammation and thrombosis [54]. Vascular and endothelial cells express receptors for VD and have the ability to convert 25 (OH) D circulating in (1,25 (OH) D). On the other hand, vitamin D deficiency along with secondary hyperparathyroidism promote hypertrophy of cardiomyocytes and vascular remodeling; studies suggest that PTH has an inflammatory effect, since it stimulates the release of cytokines [54]. In a study published in 2008, Wang [53] points out the possible interaction between VD and hypertension, and some experimental studies suggest that VD deficiency promotes the development of hypertension through the mechanism of the renin angiotensin system before mentioned. In this regard, some clinical trials have discussed associations of low VD concentrations with high blood pressure, coronary artery, calcification and cardiovascular diseases such as heart attack myocardial infarction, congestive failure [54, 55].

Some limitations of the present study must be highlighted. As we stated in previous studies [28,30], the participants in this cohort study are adults from a specific segment of the Mexican population: working class, seemingly healthy individuals. While they cannot be considered representative of the Mexican adult population as a whole, they may be considered representative of middle to low income adults residing in the urban areas of central Mexico. Other limitations are related to the measurement of nutrient consumption and effects. First, VD intake was assessed from a single measurement of FFQ, which is subject to random error that would tend to underestimate the true association between VD intake and the cardiovascular disease risk in our study. However, these errors are unlikely to affect our results, since the FFQ that we used in this study has been previously validated [31] as reasonably reflecting long-term dietary intake. Second, we did not separately compare the effects of dietary VD and supplementary VD, but since subjects’ intake of VD from supplements was minor compared with dietary intake, this was not likely to have influenced the results. Third, there is a high degree of multicollinearity among VD and other nutrients that makes it difficult to completely separate the independent effects of VD from those of nutrients like calcium and retinol. At the respect, in the present study we evaluated the relationship between dietary calcium and retinol and the 10-year risk of CVD observed null associations (data not shown). Another important limitation is that we could not measure serum 25-hydroxyvitamin D levels; therefore, we could not evaluate the relationship between serum vitamin D and cardiovascular disease risk. While our analyses considered many potential covariates that might confound the observed associations; however, the possibility of residual confounding still remains. Additionally, given that this study was cross-sectional in nature, temporal associations between VD intake and cardiovascular disease risk cannot be determined. The
major strength of the current study is the inclusion of data from a large sample size of middle-aged men and women.

In summary, our findings suggest that VD intake is associated with decreased odds of having 10-year risk of CVD. We also noted that higher VD intake reduced the odds of obesity and central obesity, as well as, the odds of low HDL-c. Additionally, the association of VD intake with 10-year CVD appeared to be mediated by BMI. Further observational research, particularly prospective studies, is needed to confirm our findings in Mexican adult population.

Supporting Information
S1 File. STROBE statement. Checklist of items that should be included in reports of cross-sectional studies.

Author Contributions
Conceptualization: PMA EDG.
Data curation: PMA EDG JS.
Formal analysis: EDG MF.
Funding acquisition: JS.
Investigation: PMA EDG JS.
Methodology: PMA EDG ESM.
Project administration: JS.
Resources: JS.
Software: PMA EDG.
Supervision: JS EDG.
Validation: PMA ESM JS.
Visualization: PMA MF.
Writing – original draft: EDG PMA.
Writing – review & editing: PMA EDG MF ESM JS.

References
1. Wolpowitz D, Gilchrest BA. The vitamin D questions: How much do you need and how should you get it? J Am Acad Dermatol 2006; 54:301–317. doi: 10.1016/j.jaad.2005.11.1057 PMID: 16443061
2. Holick MF. Vitamin D. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Disease, 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
3. Norman AW, Henry HH. Vitamin D. In: Bowman BA, Russell RM, eds. Present Knowledge in Nutrition, 9th ed. Washington DC: ILSI Press, 2006.
4. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266–281. doi: 10.1056/NEJMra070553 PMID: 17634462
5. Flores M, Sánchez-Romero LM, Macias N, Lozada A, Díaz E, Barquera S. Concentraciones séricas de vitamina D en niños, adolescentes y adultos mexicanos. Resultados de la ENSANUT 2006. Cuernavaca, México: Instituto Nacional de Salud Pública, 2011.
6. Institute of Medicine (IOM). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2011.
7. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr 2008; 88:1519–1527. doi: 10.3945/ajcn.2008.26182 PMID: 19064511
8. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet 2012; 380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0 PMID: 23245604
9. Causas seleccionadas de mortalidad por sexo 2010, INEGI. Estadísticas vitales2010:93,http://www.inegi.org.mx/prod_serv/contenidos/espanol/bvs/inegi/productos/integracion/sociodemografico/mujeres/hombres/2010/MyH_2010_Z.pdf
10. Getz GS, Reardon CA. Nutrition and cardiovascular disease. Atheroscler Thromb Vasc Biol 2007; 27:2499–2506.
11. Parker J, Hashmi O, Dutton D, Mavrodaris A, Kandala NB, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010; 65:225–236. doi: 10.1016/j.maturitas.2009.12.013 PMID: 20031348
12. Michos ED, Blumenthal RS. Vitamin D supplementation and cardiovascular disease risk. Circulation 2007; 115:827–828. doi: 10.1161/CIRCULATIONAHA.106.686238 PMID: 17309931
13. Muñoz-Aguirre P, Flores M, Macias N, Quezada AD, Denova-Gutiérrez E, Salmerón J. The effect of vitamin D supplementation on serum lipids in postmenopausal women with diabetes: A randomized controlled trial. Clin Nutr 2015; 34(5):799–804. doi: 10.1016/j.clinu.2014.07.002 PMID: 25453396
14. Zittermann A, Frisch S, Berthold HK, Göttig C, Kuhn J, Kleesiek K, Koerfer R. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89(5):1321–1327. doi: 10.3945/ajcn.2008.27004 PMID: 19321573
15. Zitterman A. Vitamin D and Cardiovascular Disease. Anticancer Res 2014; 34(9):4641–4648. PMID: 25202039
16. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89–90:387–392. doi: 10.1016/j.jbsbm.2004.03.004 PMID: 15225806
17. Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989; 13:954–959. PMID: 2786849
18. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30:980–986. doi: 10.2337/dc06-1994 PMID: 17277040
19. Borges AC, Feres T, Vianna LM, Paiva TB. Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension 1999; 34:897–901. PMID: 10523381
20. Borges AC, Feres T, Vianna LM, Paiva TB. Recovery of impaired K+ channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol. Br J Pharmacol 1999; 127:772–778. doi: 10.1038/sj.bjp.0702581 PMID: 10401569
21. Ohsawa M, Koyama T, Yamamoto K, Hiroswa S, Kamei S, Kamiyama R. 1 alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation 2000; 102:2867–2872. PMID: 11104746
22. O’Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272:H1751–758. PMID: 9139959
23. Yang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288:E125–E130. doi: 10.1152/ajpendo.00224.2004 PMID: 15367398
24. Sadeghi K, Wessner B, Laggrner U. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006; 36:361–370. doi: 10.1002/eji.200425995 PMID: 16402404
25. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83:754–759. PMID: 16600924
26. Muller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992; 4:506–512. PMID: 1337987
27. Denova-Gutiérrez E, Castaño S, Talavera JO, Flores M, Macías N, Rodríguez-Ramírez S, et al. Dietary patterns are associated with different indexes of adiposity and obesity in an urban Mexican population. J Nutr 2011; 141:921–927. doi: 10.3945/jn.110.132332 PMID: 21451126

28. Denova-Gutiérrez E, Castaño S, Talavera JO, Gallegos-Carrillo K, Flores M, Dosamantes-Carrasco D, et al. Dietary patterns are associated with metabolic syndrome in an urban Mexican population. J Nutr 2010; 140:1855–1863. doi: 10.3945/jn.110.122571 PMID: 20702749

29. Denova-Gutiérrez E, Talavera JO, Huítrón-Bravo G, Méndez-Hernández P, Salmerón J. Sweetened beverages consumption and increased risk of metabolic syndrome in Mexican adults. Public Health Nutrition 2010; 13:835–842. doi: 10.1017/S1368980009999115 PMID: 20144256

30. Denova-Gutiérrez E, Huítrón-Bravo G, Talavera JO, Castaño S, Gallegos-Carrillo K, Flores Y, et al. Dietary glycemic index, dietary glycemic load, blood lipids, and coronary heart disease. Journal of Nutrition and Metabolism. 2010.

31. Hernández-Avila M, Romieu I, Parra S, Hernández-Avila J, Madrigal H, Willett W. Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex 1998; 40:133–140. PMID: 9617194

32. Hernández-Avila JE, González-Avilés L, Rosales-Mendoza E. Sistema de Evaluación de Hábitos Nutricionales y Consumo de Nutrientes (SNUT), INSP, Cuernavaca (Mexico) (User manual. Evaluation system of nutritional habits and nutrient intake. National Institute of Public Health, Mexico); 2003. (in Spanish).

33. Willet WC. Nutritional Epidemiology. 2nd ed. New York: Oxford University Press; 1998.

34. WHO. 2008. Global strategy on diet, physical activity, and health (cited 2015 March 23) http://www.who.int/dietphysicalactivity/publications/facts/obesity/en.

35. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497. PMID: 11368702

36. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837–1847. PMID: 9603539

37. D’Agostino RB, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. Journal of the American Medical Association 2001; 286:180–187. PMID: 11448281

38. American Heart Association. Heart Attack Risk Assessment, (cited 2015 March 23) http://www.americanheart.org/preview.jhtml?id=identifier=3003499.

39. Institute of Medicine: Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011.

40. Denova-Gutiérrez E, Clark P, Muñoz-Aguirre P, Flores M, Talavera JO, Chico-Barba LG, et al. Dietary patterns are associated with calcium and vitamin D intake in an adult Mexican population. Nutr Hosp 2016; 33(3):276. doi: 10.20960/nh.276 PMID: 27513503

41. Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, Moshfegh AJ, et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010; 140:817–822. doi: 10.3945/jn.110.118539 PMID: 20181782

42. Poliquin S, Joseph L, Gray-Donald K. Calcium and vitamin D intakes in an adult Canadian population. Canadian Journal of Dietetic Practice and Research 2009; 70:21–27. doi: 10.3148/70.1.2009.01 PMID: 19261203

43. Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Marshall JW, et al. Serum 25-dihydroxyvitamin D is independently associated with high density lipoprotein cholesterol and the metabolic syndrome in men and women. Journal of Clinical Lipidology 2009; 3:289–296. doi: 10.1016/j.jacl.2009.07.003 PMID: 21291826

44. Lu L, Yu Z, Pan A, Hu FB, Franco OH, Li H, et al. Plasma 25-dihydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 2009; 32:1278–1283. doi: 10.2337/dc09-0209 PMID: 19366976

45. Lee DM, Rutter MK, O’neill TW, Boonen S, Vanderschueren D, Bouillon R, et al. Vitamin D, parathyroid hormone and the metabolic syndrome in middle aged and older European men. European Journal of Endocrinology 2009; 161:947–954. doi: 10.1530/EJE-09-0496 PMID: 19773367

46. Melamed ML, Michos ED, Post W, Astor B. 25-dihydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15):1629–1637. doi: 10.1001/archinte.168.15.1629 PMID: 18695076
47. Kayaniyl S, Vieth R, Harris SB, Retnakaran R, Knight JA, Gerstein HC, et al. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab 2011:168–175. doi: 10.1210/jc.2010-1439 PMID: 20980431

48. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011; 50:303–312. doi: 10.1016/j.plipres.2011.05.001 PMID: 21640757

49. Jaimungal S, Wehmeier K, Mooradian AD, Haas MJ. The emerging evidence for vitamin D-mediated regulation of apolipoprotein AI synthesis. Nutr Res 2011; 31:805–812. doi: 10.1016/j.nutres.2011.09.005 PMID: 22118750

50. Ramly M, Ming MF, Chlnna K, Suboh S, Pendek R. Effect of vitamin D supplementation on cardiometabolic risks and health-related quality of life among urban premenopausal women in a tropical country—a randomized controlled trial. PLoS One 2014; 9(10):e110476. doi: 10.1371/journal.pone.0110476 PMID: 25350669

51. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Arch Intern Med 2007; 167:1159–65.

52. Sun Q, Shi L, Rimm EB, Giovannucci EL, Hu FB, Manson JE, et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am J Clin Nutr 2011; 94:534–542. doi: 10.3945/ajcn.110.008763 PMID: 21653796

53. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503–511. doi: 10.1161/CIRCULATIONAHA.107.706127 PMID: 18180395

54. Lind L, Hanni A, Lithell H, Hvarfner A, Sørensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged man. Am J Hypertens 1995; 8:894–901. doi: 10.1016/0895-7061(95)00154-H PMID: 8541004

55. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96:1755–1760. PMID: 9323058